Natera Secures Japan Clearance for Signatera Test for Colorectal Cancer

▤ Summary

Natera secured Japanese clearance for its Signatera colorectal cancer test. The clearance expands the company’s ability to commercialize its oncology testing platform in a new market. This kind of regulatory milestone can support international revenue growth and broader adoption of the test. For software-industry taxonomy purposes, the closest fit is life sciences and clinical software rather than a pure SaaS event.

▦ Linked Companies